Cabaletta Bio (CABA) Operating Leases (2022 - 2026)

Cabaletta Bio (CABA) posted quarterly Operating Leases of $580000.0 for Q2 2025, down 61.18% quarter-over-quarter from $1.5 million in Q1 2025.

Cabaletta Bio (CABA) Operating Leases (2022 - 2026) Analysis & Trends

Cabaletta Bio's Operating Leases history runs 4 years deep, the most recent figure standing at $580000.0 for Q2 2025.

In Q2 2025, Operating Leases changed N/A year-over-year to $580000.0; the TTM figure through Jun 2025 stood at $580000.0 (changed N/A YoY), while the FY2024 annual figure was $2.4 million, up 63.51% from the prior year.
Operating Leases for Q2 2025 stood at $580000.0, down from $1.5 million in the prior quarter.
The five-year high for Operating Leases was $7.3 million in Q3 2024, with the low at $580000.0 in Q2 2025.
The 4-year median for Operating Leases is $1.9 million (2023), against an average of $2.3 million.
Peak annual rise in Operating Leases reached 316.88% in 2024, while the deepest fall reached 69.29% in 2024.
Cabaletta Bio's Operating Leases stood at $3.0 million in 2022, then tumbled by 50.73% to $1.5 million in 2023, then jumped by 63.51% to $2.4 million in 2024, then sank by 75.67% to $580000.0 in 2025.
Business Quant data shows CABA's Operating Leases at $580000.0 in Q2 2025, $1.5 million in Q1 2025, and $2.4 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Cabaletta Bio	466.25 Mn	466.25 Mn	-

Download Data